April 6 (Reuters) - Oncolytics Biotech Inc ONCY.O:
ONCOLYTICS BIOTECH® ANNOUNCES TYPE C FDA MEETING TO DISCUSS SINGLE-ARM REGISTRATIONAL PATHWAY FOR PELAREOREP IN ANAL CANCER
ONCOLYTICS BIOTECH INC - SCHEDULES TYPE C FDA MEETING ON APRIL 16, 2026 FOR PELAREOREP IN ANAL CANCER
ONCOLYTICS BIOTECH INC - MEETING TO DISCUSS SINGLE-ARM PIVOTAL STUDY OF PELAREOREP IN SECOND-LINE AND LATER SCAC